inclusion criteria: - clinical picture suggestive of covid-19 dated 7 days or less. - positivity of a test proving an acute sars-cov-2 infection, according to current recommendations. - absence of criteria for hospitalization or oxygen therapy according to current recommendations. - age : - greater than or equal to 60 years of age without any risk factor - or between 50 and 59 years of age and the presence of at least one of the following risk factors : - arterial hypertension under treatment (all stages) - obesity (bmi ≥30 kg/m2) - diabetes under treatment (all types) - ischemic heart disease (all stages) - heart failure (all stages) - stroke history - chronic obstructive pulmonary disease (all stages) - stage 3 chronic renal failure (30 ≤ estimated gfr < 60 ml/min/1.73 m²) - malignancies (solid tumours or blood malignancies) that are progressive or were diagnosed less than 5 years ago. - immunodeficiency - of therapeutic origin (solid organ transplant or hematopoietic stem cell transplant, cancer chemotherapy, immunosuppressive therapy, corticosteroids > 15 mg/d of prednisone equivalent taken for at least 2 months); - hiv infection with cd4<200/mm3. - valid, ambulatory person, fully able to understand the issues of the trial - beneficiary of a social security scheme - signed informed consent

inclusion criteria: - clinical picture suggestive of covid-19 dated 7 days or less. - positivity of a test proving an acute sars-cov-2 infection, according to current recommendations. - absence of criteria for hospitalization or oxygen therapy according to current recommendations. - age : - greater than or equal to 60 years of age without any risk factor - or between 50 and 59 years of age and the presence of at least one of the following risk factors : - arterial hypertension under treatment (all stages) - obesity (bmi ≥30 kg/m2) - diabetes under treatment (all types) - ischemic heart disease (all stages) - heart failure (all stages) - stroke history - chronic obstructive pulmonary disease (all stages) - stage 3 chronic renal failure (30 ≤ estimated gfr < 60 ml/min/1.73 m²) - malignancies (solid tumours or blood malignancies) that are progressive or were diagnosed less than 5 years ago. - immunodeficiency - of therapeutic origin (solid organ transplant or hematopoietic stem cell transplant, cancer chemotherapy, immunosuppressive therapy, corticosteroids > 15 mg/d of prednisone equivalent taken for at least 2 months); - hiv infection with cd4<200/mm3. - valid, ambulatory person, fully able to understand the issues of the trial - beneficiary of a social security scheme - signed informed consent

inclusion criteria: - positive sars-cov-2 infection virology test on nasopharyngeal swab - onset of symptoms < 5 days prior to nasopharyngeal swab sampling - age ≥ 60 years - valid, ambulatory person, fully capable of understanding the challenges of the tria - no hospitalization criteria according to current recommendations - signed informed consent - covered by health insurance

inclusion criteria: - positive sars-cov-2 infection virology test on nasopharyngeal swab - onset of symptoms < 5 days prior to nasopharyngeal swab sampling - age ≥ 60 years - valid, ambulatory person, fully capable of understanding the challenges of the tria - no hospitalization criteria according to current recommendations - signed informed consent - covered by health insurance